In clinical trials, MDM2 inhibitors effectively dissociate the p53/MDM2 complex, inhibit MDM2-mediated ubiquitination and degradation of p53, and induce the activation and accumulation of wild-type p53 in tumor cells.39 This evidence concerns the gene TP53 and neoplasm.